Arthneeti
NP

Natco Pharma

Q1 FY27Pharmaceuticals & Biotechnology

Natco Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹872
Market cap₹15.8K Cr
P/E13.8
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 2
MarginRank 3
CapexYes
FundraiseYes

Not discussed on this call: order book.

The short version

Domestic formulations expected to grow about 25% in volume this year (Page 4). - Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3). - Growth anticipated across key geographies: Brazil, Canada, and the U.S. PAT guidance for FY27 remains around INR 750 crores, with no change despite seasonal fluctuations.

From Natco Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 2
  • Domestic formulations expected to grow about 25% in volume this year (Page 4).
  • Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3).
  • Growth anticipated across key geographies: Brazil, Canada, and the U.S. (Page 6).
  • New product launches in Brazil planned for FY27, driven by oncology pipeline (Page 8).
  • Expect growth in international formulations supported by product launches and pipeline expansion (Page 9).
  • Overall revenue guidance for the year: gross sales between INR3,300 crores to INR3,400 crores and total sales around INR750 crores PAT (Page 6).
  • Continuous filing of 8-10 ANDAs annually with 2-3 First-to-File (FTF) targets to fuel future product launches (Page 13).
  • Long-term R&D payoffs expected over an 8-10 year horizon with higher returns (Page 14).

Profitability & Margins

See what Natco Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • NATCO plans to continue organic capex at an annual run rate of approximately INR 250-300 crores for capacity expansion and internal requirements.
  • The company is also evaluating various acquisition opportunities, both in India and internationally, requiring additional capital.
  • A proposed fundraise of INR 2,000 crores is intended to support potential acquisitions, pay off short-term loans, and cover ongoing capex.
  • Capex investments target readiness for growth opportunities already under evaluation.
  • Strategic investments include pipeline development and expanding registration capabilities, especially for 9(3) limited competition products.
  • The company aims to launch two exclusivity-based products in the next financial year and expects to file around 8-10 ANDAs annually, including 2-3 First-to-File assets.
  • Certain long-term investments have payoffs expected between 2028 and 2035, reflecting a focus on high-return projects over an 8-10 year horizon.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Natco Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers. However, relevant insights include: - The company is actively engaged in multiple markets including India, South Africa, Brazil, Canada, and the U.S., indicating ongoing and future demand. - There are different product cycles and seasonality impacting order flow (e.g., flu season boosting Adcock’s sales in South Africa). - The company has ongoing registration filings and expected product launches, such as semaglutide in South Africa (expected around 2028). - The business is evaluating acquisition opportunities indicating potential for increased future order inflows. - Growth seen in Brazil (+180%) and stable demand in Canada (INR 56 crores revenue in the quarter). - Focus on Indian R&D pipeline targeting 8-10 ANDA filings annually and 2-3 FTF filings. No specific order book or pending orders number was disclosed during the call.

Natco Pharma — Quarterly revenue & net profit

Revenue Net profit
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Natco Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Natco Pharma Q1 FY27 results?

Domestic formulations expected to grow about 25% in volume this year (Page 4). - Brazil business showing strong growth with revenue at INR178 crores, up 180% (Page 3). - Growth anticipated across key geographies: Brazil, Canada, and the U.S. PAT guidance for FY27 remains around INR 750 crores, with no change despite seasonal fluctuations.

What is Natco Pharma share price analysis?

Natco Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 13.8 with a market cap of ₹15,805 Cr. Investors should review the full earnings analysis for detailed insights.

Is Natco Pharma planning capital expenditure?

NATCO plans to continue organic capex at an annual run rate of approximately INR 250-300 crores for capacity expansion and internal requirements.

Keep Natco Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.